Effect of Ferric Carboxymaltose on Exercise Capacity in Patients with Chronic Heart Failure and Iron Deficiency

Circulation

Volumn 136, Issue 15, 2017, Pages 1374-1383

  Van Veldhuisen, Dirk J ^a   Ponikowski, Piotr ^b   Van Der Meer, Peter ^a   Metra, Marco ^c   Böhm, Michael ^d   Doletsky, Artem ^e   Voors, Adriaan A ^a   MacDougall, Iain C ^f   Anker, Stefan D ^g,h,i   Roubert, Bernard ^j   Zakin, Lorraine ^j   Cohen Solal, Alain ^k  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

^c University Hospital   (Italy)

^d SAARLAND UNIVERSITY   (Germany)

^e I M SECHENOV FIRST MOSCOW STATE MEDICAL UNIVERSITY   (Russian Federation)

^f KING S COLLEGE HOSPITAL   (United Kingdom)

^g MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^h CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

ⁱ UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^j Vifor (International) Inc   (Switzerland)

^k HÔPITAL LARIBOISIÈRE   (France)

more..

Author keywords

exercise capacity; ferric carboxymaltose; heart failure; iron deficiency

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE; FERRIC CARBOXYMALTOSE; FERRITIN; TRANSFERRIN; BIOLOGICAL MARKER; FERRIC ION; IRON; MALTOSE; OXYGEN;

ADULT; AGE DISTRIBUTION; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG TOLERABILITY; EXERCISE; EXERCISE TEST; FEMALE; FERRITIN BLOOD LEVEL; FOLLOW UP; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; IRON DEFICIENCY; MAJOR CLINICAL STUDY; MALE; NEW YORK HEART ASSOCIATION CLASS; OXYGEN CONSUMPTION; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; TRANSFERRIN BLOOD LEVEL; TREATMENT OUTCOME; TREATMENT RESPONSE; AGED; ANALOGS AND DERIVATIVES; BLOOD; CLINICAL TRIAL; DEFICIENCY; DRUG EFFECTS; EXERCISE TOLERANCE; HEART STROKE VOLUME; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY;

AGED; BIOMARKERS; EXERCISE TOLERANCE; FEMALE; FERRIC COMPOUNDS; FERRITINS; HEART FAILURE; HUMANS; IRON; MALE; MALTOSE; MIDDLE AGED; OXYGEN; QUALITY OF LIFE; STROKE VOLUME; TRANSFERRIN;

EID: 85024483330     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.117.027497     Document Type: Conference Paper

References (26)

1. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P; Authors/Task Force Members. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37:2129-2200. doi: 10.1093/eurheartj/ ehw128.
2. Van Veldhuisen DJ, Anker SD, Ponikowski P, Macdougall IC. Anaemia and iron deficiency in heart failure: mechanisms and therapeutic applications. Nat Rev Cardiol 2011; 8: 485-493. doi: 10.1038/nrcardio.2011.77.
3. Klip IT, Comin-Colet J, Voors AA, Ponikowski P, Enjuanes C, Banasiak W, Lok DJ, Rosentryt P, Torrens A, Polonski L, van Veldhuisen DJ, van der Meer P, Jankowska EA. Iron deficiency in chronic heart failure: an international pooled analysis. Am Heart J. 2013;165:575.e3-582.e3. doi: 10.1016/j. ahj.2013.01.017.
4. Okonko DO, Mandal AK, Missouris CG, Poole-Wilson PA. Disordered iron homeostasis in chronic heart failure: prevalence, predictors, and relation to anemia, exercise capacity, and survival. J Am Coll Cardiol. 2011;58:1241-1251. doi: 10.1016/j.jacc.2011.04.040.
5. Cleland JG, Zhang J, Pellicori P, Dicken B, Dierckx R, Shoaib A, Wong K, Rigby A, Goode K, Clark AL. Prevalence and outcomes of anemia and hematinic deficiencies in patients with chronic heart failure. JAMA Cardiol. 2016;1:539-547. doi: 10.1001/jamacardio.2016.1161.
6. Brownlie T 4th, Utermohlen V, Hinton PS, Haas JD. Tissue iron deficiency without anemia impairs adaptation in endurance capacity after aerobic training in previously untrained women. Am J Clin Nutr. 2004;79:437-443.
7. Jankowska EA, von Haehling S, Anker SD, Macdougall IC, Ponikowski P. Iron deficiency and heart failure: diagnostic dilemmas and therapeutic perspectives. Eur Heart J. 2013;34:816-829. doi: 10.1093/eurheartj/ ehs224.
8. Cohen-Solal A, Leclercq C, Deray G, Lasocki S, Zambrowski JJ, Mebazaa A, de Groote P, Damy T, Galinier M. Iron deficiency: an emerging therapeutic target in heart failure. Heart. 2014;100:1414-1420. doi: 10.1136/ heartjnl-2014-305669.
9. Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, Lüscher TF, Bart B, Banasiak W, Niegowska J, Kirwan BA, Mori C, von Eisenhart Rothe B, Pocock SJ, Poole-Wilson PA, Ponikowski P; FAIRHF Trial Investigators. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med. 2009;361:2436-2448. doi: 10.1056/ NEJMoa0908355.
10. Ponikowski P, van Veldhuisen DJ, Comin-Colet J, Ertl G, Komajda M, Mareev V, McDonagh T, Parkhomenko A, Tavazzi L, Levesque V, Mori C, Roubert B, Filippatos G, Ruschitzka F, Anker SD; CONFIRM-HF Investigators. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J. 2015;36:657-668. doi: 10.1093/eurheartj/ehu385.
11. Malhotra R, Bakken K, D'Elia E, Lewis GD. Cardiopulmonary exercise testing in heart failure. JACC Heart Fail. 2016;4:607-616. doi: 10.1016/j. jchf.2016.03.022.
12. Guazzi M, Adams V, Conraads V, Halle M, Mezzani A, Vanhees L, Arena R, Fletcher GF, Forman DE, Kitzman DW, Lavie CJ, Myers J. EACPR/AHA joint scientific statement. Clinical recommendations for cardiopulmonary exercise testing data assessment in specific patient populations. Eur Heart J 2012;33:2917-2927. doi: 10.1093/eurheartj/ehs221.
13. Tabet JY, Beauvais F, Thabut G, Tartière JM, Logeart D, Cohen-Solal A. A critical appraisal of the prognostic value of the VE/VCO2 slope in chronic heart failure. Eur J Cardiovasc Prev Rehabil. 2003;10:267-272. doi: 10.1097/01.hjr.0000085248.65733.ab.
14. Keteyian SJ, Patel M, Kraus WE, Brawner CA, McConnell TR, Pina IL, Seifer ES, Fleg JL, Blackburn G, Fonarow GC, Chase PJ, Piner L, Vest M, O'Connor CM, Ehrmann JK, Walsh MN, Ewald G, Bensimhon D, Russell SD; on behalf of the HF-ACTION Investigators. Variables measured during cardiopulmonary exercise testing as predictors of prognosis of mortality in chronic systolic heart failure. J Am Coll Cardiol 2016;67:780-789. doi: 10.1016/j.jacc.2015.11.050.
15. van Veldhuisen DJ, Dickstein K, Cohen-Solal A, Lok DJ, Wasserman SM, Baker N, Rosser D, Cleland JG, Ponikowski P. Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia. Eur Heart J. 2007;28:2208-2216. doi: 10.1093/eurheartj/ehm328.
16. Okonko DO, Grzeslo A, Witkowski T, Mandal AK, Slater RM, Roughton M, Foldes G, Thum T, Majda J, Banasiak W, Missouris CG, Poole-Wilson PA, Anker SD, Ponikowski P. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial. J Am Coll Cardiol. 2008;51:103-112. doi: 10.1016/j.jacc.2007.09.036.
17. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJV, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WHW, Tsai EJ, Wilkoff BL. 2013 ACCF/AHA Guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;128:e240-e327. doi: 10.1161/CIR.0b013e31829e8776.
18. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Colvin MM, Drazner MH, Filippatos G, Fonarow GC, Givertz MM, Hollenberg SM, Lindenfeld JA, Masoudi FA, McBride PE, Peterson PN, Stevenson LW, Westlake C. 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA Guideline for the management of heart failure: a report of the American College of Cardiology/ American Heart Association Task force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2016;134: e282-e293. doi: 10.1161/CIR.0000000000000435.
19. von Haehling S, Jankowska EA, van Veldhuisen DJ, Ponikowski P, Anker SD. Iron deficiency and cardiovascular disease. Nat Rev Cardiol. 2015;12:659-669. doi: 10.1038/nrcardio.2015.109.
20. Macdougall IC, Tucker B, Thompson J, Tomson CR, Baker LR, Raine AE. A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int. 1996;50:1694-1699.
21. Beck-da-Silva L, Piardi D, Soder S, Rohde LE, Pereira-Barretto AC, De Albuquerque D, Bocchi E, Vilas-Boas F, Moura LZ, Montera MW, Rassi S, Clausell N. IRON-HF study: a randomized trial to assess the effects of iron in heart failure patients with anemia. Int J Cardiol 2013; 168: 3439-3442. doi: 10.1016/j.ijcard.2013.04.181.
22. Lewis GD, Semigran MJ, Givertz MM, Malhotra R, Anstrom KJ, Hernandez AF, Shah MR, Braunwald E. Oral iron therapy for heart failure with reduced ejection fraction. Design and rationale for Oral Iron Repletion Effects on Oxygen Uptake in Heart Failure (IRONOUT HF). Circ Heart Fail 2016; 9:e000345. doi: 10.1161/CIRCHEARTFAILURE.115.000345.
23. Lewis GD, Malhotra R, Hernandez AF, McNulty SE, Smith A, Felker GM, Tang WHW, LaRue SJ, Redfield MM, Semigran MJ, Givertz MM, Van Buren P, Whellan D, Anstrom KJ, Shah MR, Desvigne-Nickens P, Butler J, Braunwald E; NHLBI Heart Failure Clinical Research Network. Effect of Oral Iron Repletion on Exercise Capacity in Patients With Heart Failure With Reduced Ejection Fraction and Iron Deficiency: The IRONOUT HF randomized clinical trial. JAMA. 2017;317:1958-1966. doi: 10.1001/ jama.2017.5427.
24. Swank AM, Horton J, Fleg JL, Fonarow GC, Keteyian S, Goldberg L, Wolfel G, Handberg EM, Bensimhon D, Illiou MC, Vest M, Ewald G, Blackburn G, Leifer E, Cooper L, Kraus WE; HF-ACTION Investigators. Modest increase in peak VO2 is related to better clinical outcomes in chronic heart failure patients: results from heart failure and a controlled trial to investigate outcomes of exercise training. Circ Heart Fail. 2012;5:579-585. doi: 10.1161/ CIRCHEARTFAILURE.111.965186.
25. Jankowska EA, Tkaczyszyn M, Suchocki T, Drozd M, von Haehling S, Doehner W, Banasiak W, Filippatos G, Anker SD, Ponikowski P. Effects of intravenous iron therapy in iron-deficient patients with systolic heart failure: a meta-analysis of randomized controlled trials. Eur J Heart Fail. 2016;18:786-795. doi: 10.1002/ejhf.473.
26. Toblli JE, Lombrana A, Duarte P, Di Genarro F. Intravenous iron reduces NTpro-brain natriuretic peptide in anemic patienst with chronic heart failure and iron deficiency. J Am Coll Cardiol 2007;50:1657-1665.